New Cancer Treatment Shows Promise Against Deadly Tumor Type

Scientists at MD Anderson Cancer Center just found a potential game changer for one of the deadliest forms of breast cancer.

Triple-negative breast cancer (TNBC) has long frustrated doctors because it survives treatments that work on other cancers. While most therapies attack cancer by damaging DNA, TNBC cells have figured out how to shrug off this damage and keep growing.

Now researchers understand why. These aggressive tumors produce excessive amounts of an enzyme called RNase H2, which acts like a repair crew that fixes DNA damage as fast as treatments can cause it.

Dr. Shiaw-Yih Lin and her team at MD Anderson decided to target this survival mechanism head-on. When they blocked RNase H2 in laboratory studies, something remarkable happened.

The cancer cells couldn't repair themselves anymore, so the DNA damage piled up. But that wasn't the only effect.

The Bright Side

Blocking RNase H2 turned out to be a two-for-one deal. The damaged DNA triggered the body's immune system to wake up and recognize the cancer as a threat.

T cells, the body's natural cancer fighters, got called to the scene and joined the attack. The tumors shrank in animal studies, offering hope that this could work in people too.

The discovery gets even better. The researchers found that RNase H2 blockers make two existing cancer drugs work better: ATR inhibitors and PARP inhibitors. This opens the door to combination treatments that could pack an even stronger punch.

"This is a one-two punch that overcomes the adaptive mechanism that triple-negative breast cancer tumors leverage to survive," Lin explained. Her team's findings appeared in Cell Reports Medicine this month.

TNBC accounts for about 15% of all breast cancers but causes a disproportionate share of deaths. It strikes younger women more often and spreads faster than other types. Because it lacks the hormone receptors that other breast cancers have, fewer treatment options exist.

The research is still in the preclinical stage, meaning it hasn't been tested in human patients yet. But RNase H2 inhibitors are already being developed by pharmaceutical companies, which could speed the path to clinical trials.

For the thousands of women diagnosed with TNBC each year, this research represents genuine hope that better treatments are on the horizon.